Virtus Logo
Contact

Our services

We perform state of the art preclinical and clinical research studies in respiratory infections and airway diseases...

Find out more

Infection rate

The overall infection rate of our current stock of rhinovirus is 82% in asthmatics, COPD and healthy volunteers.

Source : Deloitte 2015

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.

Our Vision

We perform state of the art preclinical and clinical research studies in respiratory infections and airway diseases...

Learn more

Keep Updated With Our Progress

Aceri officto dolorem quis quaeces. Volupit idi ulpariorror moleser iorempores est, volores endenda nimusda voluptam ius.

The email address is incorrect
Please agree to our Privacy and Policy
Something went wrong